The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Cerebral Cavernous Malformation
Interventions
DRUG

REC-994

REC-994 200 mg tablets

DRUG

Placebo

Placebo Tablets

Trial Locations (15)

10027

Columbia University Medical Center, New York

14642

University of Rochester Medical Center, Rochester

15260

University of Pittsburgh, Pittsburgh

19104

Thomas Jefferson University, Philadelphia

University of Pennsylvania, Philadelphia

22908

University of Virginia, Charlottesville

30322

Emory, Atlanta

32608

University of Florida, Gainesville

34987

Cleveland Clinic Florida, Port Saint Lucie

85004

Xenoscience Inc, Phoenix

90095

UCLA, Los Angeles

94304

Stanford University, Palo Alto

32207-8202

Lyerly Neurosurgery, Jacksonville

07450

Valley Hospital, Ridgewood

75390-8855

The University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

Recursion Pharmaceuticals Inc.

INDUSTRY